Nov 09, 2020 / 01:45PM GMT
Evan David Seigerman - Crédit Suisse AG - Research Division - VP & Senior Equity Research Analyst
Sorry about that for everyone who is viewing -- who is in the Regeneron session. So my name is Evan Seigerman. I'm the senior biopharma analyst here at Crédit Suisse. And welcome to Day 1 of our Virtual Health Care Conference. I really wish we're all in Scottsdale together as that would be a lot more fun, and a little easier, given some technical difficulties this morning.
But it's my pleasure to have Marion McCourt and Justin Holko from Regeneron. I'm really excited to just have a fantastic conversation about everything that's happening at Regeneron from the COVID-19 antibody cocktail, EYLEA, Dupixent and the oncology franchise.
And before we jump into Q&A, I just want to pass it over to Justin for a quick disclaimer statement. And then Marion, I want to give you the floor for a quick introduction.
Justin Holko - Regeneron Pharmaceuticals, Inc. - VP of IR
Sure. Thank you. Actually 2 disclaimer statements. The
Regeneron Pharmaceuticals Inc at Credit Suisse Healthcare Conference (Virtual) Transcript
Nov 09, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers